Edgewise Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $151.4M | $127.0M | $90.9M | $54.0M | $32.2M |
| Operating expenses | $191.4M | $158.8M | $114.4M | $71.7M | $43.2M |
| Operating income | -$191.4M | -$158.8M | -$114.4M | -$71.7M | -$43.2M |
| Pretax income | -$167.8M | -$133.8M | -$100.2M | — | — |
| Income tax expense | $4,000 | $3,000 | $4,000 | $0 | $0 |
| Net income | -$167.8M | -$133.8M | -$100.2M | -$67.6M | -$42.8M |
| Balance Sheet | |||||
| Cash and equivalents | $61.1M | $41.7M | $86.1M | $22.0M | $15.6M |
| Current assets | $543.4M | $475.5M | $327.0M | $357.0M | $283.8M |
| Total assets | $552.6M | $486.8M | $340.0M | $367.1M | $285.2M |
| Current liabilities | $27.4M | $23.9M | $16.8M | $16.6M | $10.5M |
| Total liabilities | $30.3M | $27.6M | $21.2M | $20.4M | $10.8M |
| Stockholders' equity | $522.3M | $459.2M | $318.8M | $346.7M | $274.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$143.8M | -$109.0M | -$91.9M | -$52.6M | -$33.5M |
| Depreciation and amortization | $2.1M | $2.1M | $1.6M | $368,000 | $272,000 |
| Stock-based compensation | $34.8M | $24.7M | $17.6M | $10.9M | $4.4M |
| Capital expenditure | $256,000 | $1.3M | $5.7M | $5.5M | $668,000 |
| Free cash flow | -$144.1M | -$110.3M | -$97.7M | -$58.2M | -$34.2M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 107.6M · Free float 56.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.